High Throughput PDX Screens

High-Throughput PDX Screens to Prioritize Biomarkers for Exploration in Clinical Development


Champions Oncology excels at cost-effective, high throughput PDX screens.  Performing gene differential analysis, global mutational analysis and pathway mapping, our bioinformatics scientists can help identify biomarkers of response and/or resistance. More than 80% of the models in the Champions Oncology TumorGraft® database are available for these types of studies. Models can be selected based on tumor type, or on a targeted molecular anomaly, or both to make faster go/no-go decision on the clinical advancement of agents.  These screens are enrolled on a quarterly basis and include:

  • No minimum enrollment of animals
  • Significant cost savings versus standalone studies
  • Terminal tumor collections (Snap frozen/FFPE) can be provided for target validation
  • Standards of Care response data for each model
  • Flow Cytometry, IHC and Nanostring gene expression analysis 
  • Next-Gen Sequencing (WES and RNASeq) available